Minulet (Ethinylestradiol, Gestodene)

The ethinylestradiol component provides estrogenic activity, while gestodene supplies progestogenic effects. Together they suppress the hypothalamic‑pituitary release of luteinizing hormone and follicle‑stimulating hormone, which blocks follicular development and ovulation. The progestin also thickens cervical mucus and alters the endometrial lining, creating an environment that is unfavorable for fertilization and implantation.

The specific dosing regimen for Minulet is determined by the prescribing clinician. Typically, a combined oral contraceptive is taken as one tablet daily at the same time for 21 consecutive days, followed by a pill‑free interval of 7 days, but the exact schedule and any variations must be set by a qualified healthcare provider.

Minulet must not be used during an established pregnancy; if pregnancy occurs, the product should be discontinued immediately. Data on use while breastfeeding are limited, and most guidelines advise caution or avoidance, especially in the early postpartum period, because estrogen may affect milk production. Consultation with a physician is essential before any use.

To request Minulet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements if applicable), and assist with import documentation.

Minulet contains gestodene, a third‑generation progestogen, which is associated with a slightly lower incidence of androgenic side effects such as acne compared with older agents like levonorgestrel. Efficacy in preventing pregnancy is comparable across combined oral contraceptives when taken correctly, but individual tolerability and risk profiles may differ, making personalized selection important.

Minulet tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original blister pack, protect it from excess moisture and direct sunlight, and ensure the container is tightly closed to maintain tablet integrity throughout its shelf life.

Minulet is taken orally as a tablet. The patient should swallow one tablet with water at the same time each day, preferably after a meal to reduce gastrointestinal upset. Consistent daily intake is essential for maintaining contraceptive efficacy.

The most serious adverse events linked to combined oral contraceptives like Minulet include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis (stroke or myocardial infarction), severe hypertension, and rare hepatic tumors. Patients should be educated to seek immediate medical attention if they experience symptoms such as unexplained leg pain, chest pain, severe headache, or visual changes.

Minulet is contraindicated in women with a history of thromboembolic disorders, known estrogen‑dependent tumors (e.g., breast cancer), active liver disease, uncontrolled hypertension, or those who are pregnant or breastfeeding. It should also be avoided by smokers over 35 years of age and by individuals taking medications that significantly reduce contraceptive effectiveness without appropriate medical supervision.